

## Original Research Article

# COMPARISON OF ANTIBIOTIC SUSCEPTIBILITY PATTERN AND BIOFILM FORMING ABILITY OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS ISOLATED FROM ANTERIOR NARES OF OUTPATIENTS & ADMITTED PATIENTS OF A TEACHING HOSPITAL IN THE HILLS OF KUMAON

Archana Mohan<sup>1</sup>, Priyanka Sharma<sup>2</sup>, Ravi Saini<sup>2</sup>, Vikrant Negi<sup>2</sup>

<sup>1</sup>Assistant Professor, Department of Microbiology, Venkateshwara Institute of Medical Sciences, Gajraula, Uttar Pradesh, India.

<sup>2</sup>Assistant Professor, Department of Microbiology, Soban Singh Jeena Government Institute of Medical Sciences & Research, Almora, Uttarakhand, India.

Received : 09/05/2025  
Received in revised form : 03/07/2025  
Accepted : 20/07/2025

**Corresponding Author:**

**Dr. Vikrant Negi,**

Assistant Professor, Department of Microbiology, Soban Singh Jeena Government Institute of Medical Sciences & Research, Almora, Uttarakhand, India.  
Email: negi.vikrant@gmail.com

DOI: 10.70034/ijmedph.2025.3.477

Source of Support: Nil,

Conflict of Interest: None declared

Int J Med Pub Health  
2025; 15 (3); 2597-2602

**ABSTRACT**

**Background: Aim:** Methicillin-resistant *Staphylococcus aureus* (MRSA) is a significant human pathogen associated with both hospital-acquired and community-acquired infections. Biofilm formation is an important virulence factor that contributes to its pathogenicity. This study aimed to evaluate the biofilm-forming capacity of MRSA clinical isolates from a tertiary care hospital.

**Materials and Methods:** A total of 454 *S. aureus* isolates were obtained from various clinical specimens collected at Soban Singh Jeena Government Institute of Medical Sciences and Research, located in the Kumaon region of Uttarakhand. The study population was equally divided into inpatient (IPD, n = 227) and outpatient (OPD, n = 227) groups. Nasal swabs were collected and cultured for *S. aureus* detection. Antibiotic susceptibility testing (AST) was performed using the disc diffusion method. Biofilm-forming ability was assessed using the crystal violet microtiter plate assay.

**Results:** Among IPD samples, *S. aureus* was isolated in 67 cases (29.5%) and MRSA in 22 cases (9.7%). In the OPD group, *S. aureus* was found in 33 cases (14.5%) and MRSA in 12 cases (5.3%), indicating a higher MRSA prevalence in hospitalized patients. Most isolates were resistant to cefixime and penicillin. A sex-wise comparison revealed a higher MRSA prevalence in male patients. Biofilm formation was observed in 91.7% of MRSA isolates from OPD and 63.6% from IPD.

**Conclusion:** The study highlights a significant presence of community-acquired *S. aureus* within hospital settings. The high prevalence of biofilm formation and antibiotic resistance in MRSA underscores the urgent need for enhanced surveillance and infection control measures, particularly in high-risk patient groups.

**Keywords:** Surveillance; nasal carriage; Biofilm; MRSA

## INTRODUCTION

*Staphylococcus aureus* is a Gram-positive bacterium recognized for its ability to cause a wide range of human infections, from superficial skin lesions to severe, life-threatening systemic illnesses. The pathogen's virulence is largely attributed to its

production of diverse extracellular enzymes and surface-associated factors that facilitate immune evasion, tissue invasion, and persistence.<sup>[1]</sup> Over the years, the emergence of antibiotic-resistant *S. aureus* strains has posed a significant challenge, particularly within healthcare environments. The evolution of methicillin-resistant *Staphylococcus aureus* (MRSA)

has escalated this concern due to the presence of altered penicillin-binding proteins (PBPs), which significantly reduce the efficacy of  $\beta$ -lactam antibiotics and several other antimicrobial agents.<sup>[2]</sup> Consequently, MRSA infections are often difficult to treat and require alternative therapeutic strategies. It is known that MRSA is endemic in India with variation in the antimicrobial susceptibility patterns based on geographical region.<sup>[3]</sup> As per systemic review and meta-analysis done on prevalence of Methicillin-resistant *S. aureus* (MRSA) in India, overall prevalence of MRSA was reported as 37%. Zone-wise pooled prevalence of MRSA was found as 41%, 43%, 33%, 34%, 36%, and 40% respectively for north, east, west, south, central and north-east zones.<sup>[4]</sup>

Furthermore, the irrational use of conventionally available antibiotics and ability of forming biofilms has increased antibiotic resistance among *S. aureus* and MRSA isolates often show multi-drug resistance (MDR), resistance to  $\beta$ -lactam antibiotics and tetracyclines, macrolide, chloramphenicol, and Fluoroquinolones commonly used in the treatment and management of *S. aureus* infection.<sup>[5]</sup> Biofilms are intricate microbial communities embedded within a self-produced extracellular polymeric substance (EPS) matrix. These structures adhere to both living and non-living surfaces, promoting bacterial colonization while offering increased resistance to antimicrobial agents and immune defences. Biofilm formation relies on the synthesis of polysaccharide intercellular adhesin (PIA), a  $\beta$ -1,6-linked N-acetylglucosamine. This polymer is synthesized as a gene product of the *icaADBC* operon.<sup>[6,7]</sup> Understanding the relationship between biofilm formation and methicillin resistance in *S. aureus* is of paramount importance in clinical settings. It has been suggested that biofilm formation may enhance the development and spread of antibiotic resistance as the densely packed biofilm matrix allows for the exchange of genetic material between bacterial cells, facilitating the transfer of genes encoding antimicrobial resistance.<sup>[8]</sup> Aminoglycosides, erythromycin, and fluoroquinolones are the most commonly prescribed antibiotics for MRSA treatment. Vancomycin remains the most frequently used antibiotic in the therapy of MRSA.<sup>[9]</sup>

MRSA colonization, especially in the anterior nares, plays a pivotal role in both community and hospital-associated infections. Nasal carriers may act as reservoirs, contributing to the transmission of MRSA within healthcare facilities and the general population.<sup>[10,11]</sup> The colonization dynamics and resistance profiles may differ between admitted patients who are often exposed to prolonged antibiotic use and invasive procedures and outpatients, who may carry community-acquired strains with distinct characteristics.<sup>[12]</sup>

Despite the clinical importance, limited data are available on the antibiotic resistance and biofilm-forming potential of MRSA strains colonizing the anterior nares in hospital settings, particularly in

geographically unique regions like the Kumaon hills. This study aims to compare the antibiotic susceptibility profiles and biofilm-forming capabilities of MRSA isolates obtained from the anterior nares of outpatients and admitted patients at a teaching hospital in the Kumaon region. Understanding these characteristics will provide insights into colonization patterns, inform infection control strategies, and guide targeted therapeutic interventions to mitigate the burden of MRSA-associated infections.

## MATERIALS AND METHODS

### Study Design and Sample Collection

This cross-sectional observational study was conducted in Soban Singh Jeena Government Institute of Medical Sciences and Research, Almora located in the hills of Kumaon region of Uttarakhand. Nasal swab samples were collected from both inpatients and outpatients in hospital over a defined study period. All individuals included in the study gave informed consent. Samples were collected aseptically from the anterior nostrils using sterile cotton swabs and transported to the microbiology laboratory for further analysis.

### Laboratory Processing and Identification

Nasal swabs were inoculated onto mannitol salt agar (MSA) and 5% sheep blood agar plates. The plates were incubated aerobically at 37°C for 24 h. Colonies displaying typical morphology of *S. aureus* on MSA were further processed for identification. Initial identification was done using Gram staining and standard biochemical tests including catalase test, slide and tube coagulase test, DNase test and phosphatase test. Only isolates confirmed as *S. aureus* were included in further analysis.

### Antimicrobial susceptibility testing (AST)

Antibiotic susceptibility testing was performed using the Kirby-Bauer disk diffusion method (13) following Clinical and Laboratory Standards Institute (CLSI) guidelines. A bacterial suspension of each isolate was prepared and adjusted to the 0.5 McFarland turbidity standard. The standardized inoculum was then spread evenly on Mueller-Hinton agar (MHA) plates, and antibiotic-impregnated disks (HiMedia, Mumbai, India) were placed on the agar surface. The antibiotics tested included penicillin, cefoxitin, cefazolin, clindamycin, erythromycin, linezolid, cotrimoxazole, gentamicin, and ciprofloxacin. Methicillin resistance was examined using cefoxitin, which served as a surrogate marker. Isolates showing a zone of inhibition of  $\leq 21$  mm were considered methicillin-resistant and further confirmed using the PBP2a latex agglutination test, which detects penicillin-binding protein 2a (PBP2a) encoded by the *mecA* gene. After incubation at 37°C for 18–24 hours, the diameter of the zones of inhibition around each disc was measured in millimetres. Results were interpreted according to the CLSI breakpoints.

### Biofilm Formation Assay

Biofilm formation was assessed using the Crystal Violet Assay, following a modified protocol based on Stepnovich et al. (14). The bacterial isolates were initially grown on Tryptic Soy Agar (TSA) plates for 24 hours. Subsequently, 3–4 well-isolated colonies were transferred to test tubes containing 10 mL of Tryptic Soy Broth (TSB) supplemented with 1% glucose. The cultures were incubated overnight at 37°C and adjusted to a turbidity equivalent to 0.5 McFarland standard.

For the assay, 100 µL of the adjusted bacterial suspension from each strain was inoculated in triplicate into wells of a sterile 96-well polystyrene microtiter plate and incubated at 37°C for 24 hours. After incubation, the wells were gently aspirated and washed four times with 200 µL of phosphate-buffered saline (PBS; pH 7.2) to remove non-adherent cells. The remaining adherent biofilm was fixed with 2% sodium acetate, followed by staining with 0.1% crystal violet solution. The plate was incubated at room temperature for 5 minutes, after which excess stain was removed and the wells were rinsed twice with deionized water. After drying, 95% ethanol was added to each well to make the bound dye soluble.

The optical density (OD) of each well was then measured at 595 nm using a microplate reader. The biofilm-forming ability of each isolate was interpreted based on the OD values. The cut-off OD was defined as the mean OD of the negative control plus three times its standard deviation ( $OD_c = \text{mean OD of negative control} + 3 \times \text{SD}$ ). An OD value  $\geq 3.0$  was used as the upper threshold for strong biofilm production. *S. aureus* ATCC 35556 served as the positive control, while sterile TSB was used as the negative control. All media, reagents, and antibiotic discs were obtained from HiMedia Laboratories Pvt. Ltd., Mumbai, India.

### Statistical analysis

All collected data were initially entered into Microsoft Excel and subsequently analyzed using SPSS software (version 21). The Chi-square test was applied for comparison of categorical variables, while the Student's *t*-test (two-tailed) was used for continuous variables. A *p*-value of less than 0.05 was considered statistically significant.

## RESULTS

### Demographics of the patients and *S. aureus* isolates

A total of 454 clinical samples were collected during the study period, of which 227 samples were taken from inpatients (IPD) and 227 from outpatients (OPD). In the OPD, 121 patients (53.3%) were male and 106 (46.7%) were female. In the IPD, 127 patients (55.9%) were male and 100 (44.1%) were female. The mean age of OPD patients was  $46.5 \pm 16.8$  years (range 12–98 years), while the mean age of IPD patients was  $43.5 \pm 14.1$  years (range 17–87

years). In the IPD group, 127 (55.9%) were males and 100 (44.1%) were females. In IPD samples, *S. aureus* was found in 67 cases (29.5%), Methicillin-resistant *S. aureus* (MRSA) in 22 cases (9.7%), and coagulase-negative staphylococci (CONS) in 14 cases (6.2%). Additionally, 19 isolates (8.4%) were identified as *Escherichia coli*, 83 (36.6%) as gram-positive bacilli (GPB), and 23 (10.1%) as *Klebsiella* species. In the OPD group, the most frequently isolated organisms were GPB in 107 cases (47.1%) and CONS in 45 cases (19.8%). Other isolates included *S. aureus* in 33 cases (14.5%), MRSA in 12 cases (5.3%), *E. coli* in 15 cases (6.6%), and *Klebsiella* spp. in 15 cases (6.6%). Data showed the prevalence of MRSA and *S. aureus* in hospitalized patients, whereas CONS and GPB were more frequently isolated from outpatients.

### Antibiotic Susceptibility


Methicillin-resistant *S. aureus* (MRSA) was isolated from 12 of the 227 OPD patients and 22 of the 227 IPD patients.



**Figure 1: Heatmap representation of antibiotic susceptibility profiles of *Staphylococcus aureus* MRSA isolates from inpatients (IPD) and outpatients (OPD). Each row represents an isolate and each column represents an antibiotic tested**

All 12 OPD isolates and all 22 IPD isolates were resistant to penicillin and cefoxitin. High susceptibility to linezolid was observed in both groups (83.3% of OPD isolates vs. 81.8% of IPD isolates). Susceptibility to ciprofloxacin and cotrimoxazole was moderate in both groups (58.3% vs. 68.2% for ciprofloxacin; 66.7% vs. 59.1% for cotrimoxazole, OPD vs. IPD).

In contrast, only 8.3% of OPD isolates and 13.6% of IPD isolates were susceptible to clindamycin, and only 33.3% of OPD isolates versus 13.6% of IPD isolates were susceptible to erythromycin (Figure 1). These findings indicate very high resistance to penicillin, cefoxitin, clindamycin, and erythromycin in MRSA from both groups (Figure 2). In each case, no statistically significant differences in susceptibility were observed between OPD and IPD isolates. These findings indicate broadly similar resistance patterns in nasal MRSA from outpatients and inpatients.



**Figure 2: Comparison of antibiotic resistance percentages in methicillin-resistant *Staphylococcus aureus* (MRSA) isolates from inpatients (IPD) and outpatients (OPD). The bar graph shows the proportion (%) of resistant isolates for each antibiotic tested. Red bars represent IPD isolates, while blue bars represent OPD isolates.**

### Biofilm Formation

The biofilm-forming ability of MRSA isolates was classified as strong, moderate, weak, or non-forming. Among the 12 OPD MRSA isolates, 25.0% (3 isolates) were strong biofilm producers, 8.3% moderate (1 isolate), 58.3% weak (7 isolate), and 8.3% (1 isolate) showed no biofilm formation. Clinical history analysis revealed that strong biofilm production was observed in cases associated with chest pain, ulcers, and fever, affecting patients working as labourers, teachers, and truck drivers. The only moderate producer was associated with a patient with a history of heart disease. Weak biofilm producers were associated with diverse clinical conditions such as joint pain, urinary tract infection (UTI), body pain, and oesophageal irritation, suggesting that even mild or non-specific complaints may contain virulent strains capable of forming biofilms. Interestingly, patients with diabetes and hypertension were mostly associated with either weak or non-biofilm-forming strains. Of the 22 IPD MRSA isolates, 22.7% (5 isolates) were strong producers, 9.1% moderate (2 isolates), 31.8% weak (7 isolates), and 36.4% (8 isolates) non-producers. When correlated with patient's clinical history, strong biofilm producers were mostly isolated from individuals with diabetes (n=3), while the remaining two were associated with abdominal pain and fever. Moderate biofilm producers were also from individuals with diabetes. Weak biofilm production was detected in isolates from a diverse set of clinical conditions, including fever, renal colic, electric shock, and diabetes. Non-biofilm producers were frequently associated with acute conditions such as fever (n=3) and pancreatitis (n=2), as well as diabetes (n=1). Notably, diabetes appeared to be a common coexisting condition among biofilm-producing isolates, suggesting a possible link between chronic metabolic conditions and enhanced biofilm formation potential in MRSA.

## DISCUSSION

*S. aureus* infections pose a great burden to health, especially in low and middle-income countries. Although *S. aureus* exists as a normal flora in the human body, it remains a versatile and potent pathogen as it is one of the common causes of nosocomial and community-borne infections. They are significantly associated with various mild to severe life-threatening infections due to their ability to produce biofilms.<sup>[6,15]</sup> Despite many efforts, the number of antimicrobial resistant organisms is increasing consistently, resulting in frequent nosocomial infections in hospitals, extremely difficult clinical treatment, high mortality rates, and considerable economic losses.<sup>[2]</sup> In this regard, the screening of virulence characteristics and multi-drug resistance in *S. aureus* from clinical isolates can be helpful in the prevention and treatment of infections caused by these bacteria. In the present study, *S. aureus* strains isolated from both outpatient (OPD) and inpatient (IPD) populations were evaluated for methicillin resistance and biofilm-forming capacity. The overall rate of MRSA was higher among inpatients than in outpatients, indicating a higher burden of resistant strains in hospitalized individuals. This finding is consistent with previous reports indicating that hospital-associated MRSA (HA-MRSA) is more prevalent in inpatient settings due to factors such as antibiotic exposure, invasive procedures, and longer hospital stay.<sup>[12,16-18]</sup> Consistent with its well-known adaptability, *S. aureus* has displayed significant resistance to numerous antibiotics in clinical settings. In our study, most isolates exhibited resistant to cefixime and penicillin. These findings are consistent with other studies from Nepal.<sup>[19,20]</sup> The well-documented ability of *S. aureus* in developing resistance to therapeutic agents has been recognized since the emergence of penicillin resistance, particularly in response to selective antibiotic pressure.<sup>[21]</sup> Another study from similar geographical region to current study was conducted in Garhwal region of Uttarakhand where higher drug resistance was observed in *S. aureus* isolated from anterior nares of medical students with longer hospital exposure compared to first year medical students who were not posted in hospital.<sup>[22]</sup> When comparing MRSA prevalence based on sex, our findings revealed that male patients were more frequently affected (38%) than female patients. This gender-based distribution aligns with previous observations, as several studies have reported higher MRSA prevalence in men, which may be attributed to factors such as greater colonization rates and differences in hygiene practices.<sup>[23,24]</sup> The biofilm-forming ability of MRSA isolates was also evaluated, as it plays a key role in immune evasion, bacterial persistence, and treatment failure. A large proportion of MRSA isolates from both OPD and IPD groups displayed biofilm-forming capacity,



although with varying degrees of intensity. Among OPD isolates, 91.7% exhibited biofilm production, with 25% classified as strong producers. In comparison, 63.6% of IPD isolates were biofilm producers, of which 22.7% showed strong biofilm formation. In our study, most strains were weak biofilm producers, while only some isolates were highly virulent and strongly adhered. Our results align with previous studies, which reported the majority of weak biofilm producers in the *S. aureus* strains.<sup>[25,26]</sup> These observations support the evidence that biofilm formation is a common and significant virulence trait in MRSA, contributing to chronic and recurrent infections.<sup>[27]</sup>

To further explore the relationship between host factors and bacterial behavior, we analyzed the resistance and biofilm-forming characteristics of MRSA isolates in relation to patient health status. Interestingly, in the IPD group, two MRSA isolates obtained from diabetic patients exhibited resistance to all tested antibiotics. One of these was a strong biofilm producer, while the other showed no biofilm formation. This dual observation underlines the complex interplay between biofilm formation, antimicrobial resistance and host factors such as diabetes. The strong biofilm-producing, multi-drug-resistant isolate is consistent with previous studies that highlight how biofilms contribute to antibiotic tolerance by impeding drug penetration, facilitating horizontal gene transfer and promoting persistent cell populations.<sup>[28,29]</sup> However, the presence of a non-biofilm-producing isolate with complete resistance suggests that biofilm-independent mechanisms – such as the acquisition of mobile genetic elements or chromosomal mutations – also play an important role in resistance.<sup>[30]</sup> The fact that both patients had diabetes supports existing evidence that chronic metabolic conditions may predispose individuals to colonization by highly resistant and potentially persistent MRSA strains.<sup>[31]</sup> These findings highlight the need for tailored surveillance and treatment strategies, particularly in vulnerable populations with underlying health conditions (28). Diabetes emerged as a frequently associated among patients harboring strong and moderate biofilm-producing MRSA strains, particularly in the IPD group. This observation is consistent with previous studies suggesting that chronic metabolic conditions such as diabetes may impair host immune responses and promote colonization by biofilm-forming pathogens.<sup>[32,33]</sup> Additionally, several MRSA isolates with strong or moderate biofilm capacity were recovered from patients presenting with relatively non-specific

The study also found that while strong biofilm formation was not limited to any specific occupation or residential status, but it was observed more frequently in those isolated from patients with chronic diseases such as diabetes, hypertension and heart disease. This emphasizes the need for improved screening and infection control strategies, particularly in vulnerable populations with co-

morbidities. Overall, these findings reinforce the clinical significance of biofilm formation in MRSA and underscore the continued importance of antimicrobial surveillance in both community and hospital settings. As MRSA strains continue to evolve, understanding their resistance profiles and virulence mechanisms remains critical to improve patient outcomes.

## CONCLUSION

The present study highlights the clinical challenge posed by *S. aureus*, particularly methicillin-resistant strains, in both hospital and community settings. A higher prevalence of MRSA was observed among inpatients, emphasizing the important role of hospitalization, invasive procedures, and antibiotic exposure in the emergence of resistant strains. Antimicrobial resistance, particularly to  $\beta$ -lactam antibiotics such as penicillin and cefixime, was widespread, consistent with global trends. A large proportion of MRSA isolates were found to have the ability to form biofilms, a major virulence factor associated with long-term infection and treatment failure. The association of biofilm production with chronic diseases such as diabetes and hypertension further underscores the frailty of immunocompromised patients.

## REFERENCES

1. McGavin MJ, Heinrichs DE. The Staphylococci and Staphylococcal Pathogenesis. *Front Cell Infect Microbiol* [Internet]. 2012;2. Available from: <http://journal.frontiersin.org/article/10.3389/fcimb.2012.00066/abstract>
2. Guo Y, Song G, Sun M, Wang J, Wang Y. Prevalence and Therapies of Antibiotic-Resistance in *Staphylococcus aureus*. *Front Cell Infect Microbiol* [Internet]. 2020 Mar 17;10. Available from: <https://www.frontiersin.org/article/10.3389/fcimb.2020.00107/full>
3. Agarwal L, Singh A, Sengupta C, Agarwal A. Nasal carriage of Methicillin- and Mupirocin-resistant *S. aureus* among health care workers in a tertiary care hospital. *J Res Pharm Pract* [Internet]. 2015;4(4):182. Available from: <http://www.jrpp.net/text.asp?2015/4/4/182/167046>
4. Patil SS, Suresh KP, Shinduja R, Amachawadi RG, Chandrashekar S, Pradeep S, et al. Prevalence of Methicillin-resistant *Staphylococcus Aureus* in India: A Systematic Review and Meta-analysis. *Oman Med J* [Internet]. 2022 Jul 31;37(4):e440–e440. Available from: <https://omjonline.org/articleDetails.aspx?coType=1&ald=3163>
5. Piechota M, Kot B, Frankowska-Maciejewska A, Gruzewska A, Woźniak-Kosek A. Biofilm Formation by Methicillin-Resistant and Methicillin-Sensitive *Staphylococcus aureus* Strains from Hospitalized Patients in Poland. *Biomed Res Int* [Internet]. 2018 Dec 27;2018:1–7. Available from: <https://www.hindawi.com/journals/bmri/2018/4657396/>
6. Schilcher K, Horswill AR. Staphylococcal Biofilm Development: Structure, Regulation, and Treatment Strategies. *Microbiol Mol Biol Rev* [Internet]. 2020 Aug 19;84(3). Available from: <https://journals.asm.org/doi/10.1128/MMBR.00026-19>
7. Peng Q, Tang X, Dong W, Sun N, Yuan W. A Review of Biofilm Formation of *Staphylococcus aureus* and Its Regulation Mechanism. *Antibiotics* [Internet]. 2022 Dec 22;12(1):12. Available from: <https://www.mdpi.com/2079-6382/12/1/12>
8. Parastan R, Kargar M, Solhjoo K, Kafizadeh F. *Staphylococcus aureus* biofilms: Structures, antibiotic resistance, inhibition, and vaccines. *Gene Reports* [Internet]. 2020 Sep;20:100739. Available

- from:  
<https://linkinghub.elsevier.com/retrieve/pii/S2452014420301539>
9. Cong Y, Yang S, Rao X. Vancomycin resistant *Staphylococcus aureus* infections: A review of case updating and clinical features. *J Adv Res* [Internet]. 2020 Jan;21:169–76. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2090123219301638>
  10. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis* [Internet]. 2005 Dec;5(12):751–62. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1473309905702954>
  11. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev* [Internet]. 1997 Jul;10(3):505–20. Available from: <https://journals.asm.org/doi/10.1128/CMR.10.3.505>
  12. David MZ, Daum RS. Community-Associated Methicillin-Resistant *Staphylococcus aureus*: Epidemiology and Clinical Consequences of an Emerging Epidemic. *Clin Microbiol Rev* [Internet]. 2010 Jul;23(3):616–87. Available from: <https://journals.asm.org/doi/10.1128/CMR.00081-09>
  13. Murray PR, Niles AC, Heeren RL. Comparison of a highly automated 5-h susceptibility testing system, the Cobas-Bact, with two reference methods: Kirby-Bauer disk diffusion and broth microdilution. *J Clin Microbiol* [Internet]. 1987 Dec;25(12):2372–7. Available from: <https://journals.asm.org/doi/10.1128/jcm.25.12.2372-2377.1987>
  14. STEPANOVIĆ S, VUKOVIĆ D, HOLA V, BONAVENTURA G DI, DJUKIĆ S, ČIRKOVIĆ I, et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. *APMIS* [Internet]. 2007 Aug 10;115(8):891–9. Available from: [https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0463.2007.apm\\_630.x](https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0463.2007.apm_630.x)
  15. Donlan RM. Biofilms: Microbial Life on Surfaces. *Emerg Infect Dis* [Internet]. 2002 Sep;8(9):881–90. Available from: [http://wwwnc.cdc.gov/eid/article/8/9/02-0063\\_article.htm](http://wwwnc.cdc.gov/eid/article/8/9/02-0063_article.htm)
  16. Pai V, Rao VI, Rao SP. Prevalence and Antimicrobial Susceptibility Pattern of Methicillin-resistant *Staphylococcus Aureus* [MRSA] Isolates at a Tertiary Care Hospital in Mangalore, South India. *J Lab Physicians* [Internet]. 2010 Jul 29;2(02):082–4. Available from: <https://jlabphy.org/prevalence-and-antimicrobial-susceptibility-pattern-of-methicillin-resistant-staphylococcus-aureus-mrsa-isolates-at-a-tertiary-care-hospital-in-mangalore-south-india/>
  17. Mahajan RK, Sharma S, Sachan S, Chhakchhuak Z, Dhawan A. Pattern of methicillin resistant *Staphylococcus aureus* (MRSA) in clinical isolates from a tertiary care hospital. *Indian J Microbiol Res* [Internet]. 2024 Sep 28;11(3):170–4. Available from: <https://ijmronline.org/article-details/22881>
  18. Köck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe. *Eurosurveillance* [Internet]. 2010 Oct 14;15(41). Available from: <https://www.eurosurveillance.org/content/10.2807/es.e15.41.19688-en>
  19. Sah P, Raj Rijal K, Shakya B, Raj Tiwari B, Ghimire P. Nasal Carriage Rate of *Staphylococcus aureus* in Hospital Personnel of National Medical College and Teaching Hospital and their Antibiotic Susceptibility Pattern. *J Heal Allied Sci* [Internet]. 2019 Nov 24;3(1):21–3. Available from: <https://www.jhas.org.np/jhas/index.php/jhas/article/view/47>
  20. Ansari S, Nepal HP, Gautam R, Rayamajhi N, Shrestha S, Upadhyay G, et al. Threat of drug resistant *Staphylococcus aureus* to health in Nepal. *BMC Infect Dis* [Internet]. 2014 Dec 22;14(1):157. Available from: <https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-157>
  21. Skov R, Smyth R, Larsen AR, Bolmström A, Karlsson A, Mills K, et al. Phenotypic Detection of Methicillin Resistance in *Staphylococcus aureus* by Disk Diffusion Testing and Etest on Mueller-Hinton Agar. *J Clin Microbiol* [Internet]. 2006 Dec;44(12):4395–9. Available from: <https://journals.asm.org/doi/10.1128/JCM.01411-06>
  22. Sharma S, Pal S, Negi V, Juyal D, Sharma M, Prakash R. *Staphylococcus aureus* including MRSA nasal carriage among hospital exposed and unexposed medical students. *J Family Med Prim Care*. 2020;9(9):4936–4941. Published 2020 Sep 30. doi:10.4103/jfmpe.jfmpe.820.20
  23. Alhunaif SA, Almansour S, Almutairi R, Alshammari S, Alkhonain L, Alalwan B, et al. Methicillin-Resistant *Staphylococcus Aureus* Bacteremia: Epidemiology, Clinical Characteristics, Risk Factors, and Outcomes in a Tertiary Care Center in Riyadh, Saudi Arabia. *Cureus* [Internet]. 2021 May 10; Available from: <https://www.cureus.com/articles/57466-methicillin-resistant-staphylococcus-aureus-bacteremia-epidemiology-clinical-characteristics-risk-factors-and-outcomes-in-a-tertiary-care-center-in-riyadh-saudi-arabia>
  24. Ghia CJ, Waghela S, Rambhad G. A Systemic Literature Review and Meta-Analysis Reporting the Prevalence and Impact of Methicillin-Resistant *Staphylococcus aureus* Infection in India. *Infect Dis Res Treat* [Internet]. 2020 Jan 5;13. Available from: <https://journals.sagepub.com/doi/10.1177/1178633720970569>
  25. Kadkhoda H, Ghalavand Z, Nikmanesh B, Kodori M, Houri H, Taghizadeh Maleki D, et al. Characterization of biofilm formation and virulence factors of *Staphylococcus aureus* isolates from paediatric patients in Tehran, Iran. *Iran J Basic Med Sci* [Internet]. 2020 May;23(5):691–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32742608>
  26. Jomehzadeh N, Emrani SS. Assessment of biofilm formation, antibiotic resistance patterns, and the prevalence of adhesion-related genes in clinical *Staphylococcus aureus* isolates. *Heliyon* [Internet]. 2025 Jan;11(1):e41537. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2405844024175688>
  27. Otto M. *Staphylococcal Biofilms*. In 2008. p. 207–28. Available from: [http://link.springer.com/10.1007/978-3-540-75418-3\\_10](http://link.springer.com/10.1007/978-3-540-75418-3_10)
  28. Mah T-FC, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. *Trends Microbiol* [Internet]. 2001 Jan;9(1):34–9. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0966842X00019132>
  29. Sharma D, Misba L, Khan AU. Antibiotics versus biofilm: an emerging battleground in microbial communities. *Antimicrob Resist Infect Control* [Internet]. 2019 Dec 16;8(1):76. Available from: <https://aricjournal.biomedcentral.com/articles/10.1186/s13756-019-0533-3>
  30. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. *Staphylococcus aureus* biofilms. *Virulence* [Internet]. 2011 Sep 27;2(5):445–59. Available from: <http://www.tandfonline.com/doi/abs/10.4161/viru.2.5.17724>
  31. Donlan RM. Role of Biofilms in Antimicrobial Resistance. *ASAIJ* [Internet]. 2000 Nov;46(6):S47–52. Available from: <http://journals.lww.com/00002480-200011000-00037>
  32. Mamdoh H, Hassanein KM, Eltoony LF, Khalifa WA, Hamed E, Alshammari TO, et al. Clinical and Bacteriological Analyses of Biofilm-Forming *Staphylococci* Isolated from Diabetic Foot Ulcers. *Infect Drug Resist* [Internet]. 2023 Mar;Volume 16:1737–50. Available from: <https://www.dovepress.com/clinical-and-bacteriological-analyses-of-biofilm-forming-staphylococci-peer-reviewed-fulltext-article-IDR>
  33. Tayebi Z, Fazeli M, Hashemi A, Abdi S, Dadashi M, Nasiri MJ, et al. Molecular characterization of invasive *Staphylococcus aureus* strains isolated from patients with diabetes in Iran: USA300 emerges as the major type. *Infect Genet Evol* [Internet]. 2021 Jan;87:104679. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1567134820305104>